Agreements reached under this partnership
Business Alliances- 1
Conduct research to evaluate the efficacy of HGF for CIPN
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The project will account for a minimal proportion of R&D expenses
| Item | Details |
|---|---|
| Name of alliance partner | Yokohama City University, a public university corporation |
| Alliance partner's business activities | Research conducted by the Graduate School of Nanobioscience, including a study evaluating the efficacy of HGF for peripheral neuropathy |
| Alliance partner's location | Yokohama, Kanagawa Prefecture |
| Type of alliance | Business Alliances |
| Details of the alliance | Conduct research to evaluate the efficacy of HGF for CIPN |
| Impact on Business Performance | The project will account for a minimal proportion of R&D expenses |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No standard preventive or treatment methods have been established for CIPN, and unmet medical needs are high. The research will evaluate the efficacy of HGF and contribute to the development of new treatment strategies. The company also explained that the research expenses related to this project will account for a minimal proportion of total R&D expenses.